Palpation Imaging To Augment Clinical Breast Examination
Brussels - Medical Tactile Inc. (MTI) has announced that it will be presenting at Medtech Insight's "Investment In Innovation (In3) EUROPE: A Preview of Early-Stage Medical Technology Companies." MedTech Insight attendees will learn about Palpation Imaging for the Clinical Breast Exam using tactile sensing technology manufactured by Medical Tactile Inc.
Steve Weiss, MTI CEO, will outline plans for the company's first product: the SureTouch Visual Mapping System, FDA Approved to digitally document palpable breast lesions.
"Introduction of the SureTouch Visual Mapping System at both the National Consortium of Breast Centers (NCBC) and American Colleague of Breast Surgeons (ASBS) Annual Meetings last winter was revolutionary," stated Randee Wood, Market Developer for Medical Tactile. "Physicians were surprised how easily they could interpret SureTouch images and were impressed with the speed at which the system printed their physical findings into customized reports."
"The SureTouch Visual Mapping System is the first electronic documentation and palpation imaging system poised to clarify medico-legal issues and improve patient and physician confidence by digitally recording manual palpation," says MTI's lead clinical research partner, Dr. Cary Kaufman, Clinical Faculty Member University of Washington and Medical Director of the Bellingham Breast Center.
Manual breast examination is the oldest and most established method of breast examination accessible to all women. "Presenting at Medtech Insight's first In3 meeting in Europe gives us an opportunity to seek investment partners globally," added Wood.
MTI launches SureTouch sales 4th quarter with order commitments for delivery 6 to 8 weeks from launch. The SureTouch System retails for $12,500 US. Target customers are breast surgeons and clinicians performing manual breast examinations at clinics, community outreach programs and screening centers worldwide.
We are committed to creating an affordable, fast and easy-to-use device that will enhance and quantify the traditional process of manual palpation in breast cancer screening," says Weiss. Steve Weiss, MTI CEO, has over 25 years of management experience as CEO and in other senior executive positions from inception to successful IPO and/or acquisition. Companies include, Board of Directors and Chief Executive Officer of Lumisys, Inc., where he executed a successful IPO in November 1995 (NASDAQ:LUMI) before being acquired by Eastman Kodak in late 2000. Prior to that Mr. Weiss was a co-founder and Board Member of Virtual Imaging, where he last held the position of President (1985-1990).
MTI is an emerging manufacturer developing and marketing unique medical devices for breast cancer detection based on tactile sensing technology. MTI's first product provides the first independent confirmation and documentation of clinical breast examination with potential to reduce breast cancer morbidity and possibly mortality.
SOURCE: Medtech Insight